FGFR抑制在尿路上皮癌中的应用
本综述系统检索1995至2024年PubMed与MEDLINE中FGFR抑制剂治疗尿路上皮癌的原始文献,由国际专家小组撰写协作性叙述综述。FGFR3体细胞改变见于高达70%的低级别非肌层浸润性膀胱癌,与非炎症肿瘤微环境相关但似乎不影响系统免疫治疗反应;多种泛FGFR抑制剂已在转移性尿路上皮癌中研究,新型膀胱内给药系统有望改变早期尿路上皮癌治疗格局。
要点
- FGFR3体细胞改变见于高达70%的低级别非肌层浸润性膀胱癌。
- FGFR3改变与低级别/低分期肿瘤相关,但对复发或进展的预后价值尚不一致。
- FGFR3改变肿瘤与免疫治疗反应的关系:似乎不影响系统免疫治疗反应。
核心结论
- 随着对膀胱癌生物学、新型诊断和给药方式的理解加深,作者认为FGFR抑制将引领膀胱癌精准治疗的进展。
研究设计与样本
- 协作性叙述综述:系统检索PubMed和MEDLINE数据库中1995至2024年FGFR抑制剂与尿路上皮癌相关的原始文献,检索词为「FGFR」和「膀胱癌」,并由在FGFR抑制剂治疗方面经验丰富的国际专家小组综合撰写。
主要发现
- 体细胞FGFR3改变见于高达70%的低级别非肌层浸润性膀胱癌,激活下游信号级联并最终导致细胞增殖。
- FGFR3改变与低级别/低分期肿瘤相关,但这些改变是否赋予癌症复发或进展的预后风险,各研究间几乎没有一致性。
- FGFR3改变肿瘤与未炎症的肿瘤微环境相关,但似乎不影响对系统免疫治疗的反应。
- 多种泛FGFR抑制剂已在转移性尿路上皮癌中研究。
- 随着新型膀胱内药物递送系统的引入,FGFR抑制剂有望改变早期尿路上皮癌的治疗格局。
临床怎么用
- 2024年美国食品药品监督管理局(FDA)批准厄达替尼用于治疗伴有FGFR3改变的转移性尿路上皮癌。
- 作者认为,随着对膀胱癌生物学的深入理解、新型诊断方法和改进的药物递送方式,FGFR抑制将引领膀胱癌精准治疗的进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The 2024 US Food and Drug Administration approval of erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with FGFR3 alterations ushered in the era of targeted therapy for bladder cancer. In this review, we summarize the effects of FGFR pathway alterations in oncogenesis, clinical data supporting FGFR inhibitors in the management of bladder cancer, and the challenges that remain. METHODS: Original articles relevant to FGFR inhibitors in urothelial cancer between 1995 and 2024 were systematically identified in the PubMed and MEDLINE databases using the search terms "FGFR" and "bladder cancer". An international expert panel with extensive experience in FGFR inhibitor treatment was convened to synthesize a collaborative narrative review. KEY FINDINGS AND LIMITATIONS: Somatic FGFR3 alterations are found in up to 70% of low-grade non-muscle-invasive bladder cancers; these activate downstream signaling cascades and culminate in cellular proliferation. Beyond a link to lower-grade/lower-stage tumors, there is little consistency regarding whether these alterations confer prognostic risks for cancer recurrence or progression. FGFR3-altered tumors have been linked to a non-inflamed tumor microenvironment, but paradoxically do not seem to impact the response to systemic immunotherapy. Several pan-FGFR inhibitors have been investigated in mUC. With the introduction of novel intravesical drug delivery systems, FGFR inhibitors are poised to transform the therapeutic landscape for early-stage UC. CONCLUSIONS AND CLINICAL IMPLICATIONS: With deepening understanding of the biology of bladder cancer, novel diagnostics, and improved drug delivery methods, we posit that FGFR inhibition will lead the way in advancing precision treatment of bladder cancer.
引用
- Li R, Linscott J, Catto JWF, et al. FGFR Inhibition in Urothelial Carcinoma. Eur Urol. 2024. PMID: 39353825. doi:10.1016/j.eururo.2024.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。